文献速递艾滋病与性传播感染

初治成人启动多替拉韦加拉米夫定或多替拉韦/恩曲他滨/替诺福韦艾拉酚胺方案后精浆与直肠液中HIV RNA的衰减

Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.
PubMed 文献 · J Infect Dis · 2023-01-01

本随机多中心先导试验将抗逆转录病毒初治男性按2:1随机分配至多替拉韦加拉米夫定组或比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺组,在基线和多个时间点检测血浆、精浆和直肠液中HIV-1 RNA。两组各时间点HIV-1 RNA自基线的中位下降及达到抑制的中位时间均无显著差异;多替拉韦加拉米夫定组精浆和直肠液中HIV-1 RNA抑制的中位时间短于血浆。

要点

  • 多替拉韦加拉米夫定组与比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺组血浆、精浆和直肠液中HIV-1 RNA衰减无显著差异。
  • 多替拉韦加拉米夫定组精浆和直肠液中HIV-1 RNA抑制的中位时间短于血浆。
  • 多替拉韦加拉米夫定组精浆和直肠液中HIV-1 RNA快速抑制,衰减模式与血浆不同。

核心结论

  • 多替拉韦加拉米夫定与比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺两组间血浆、精浆和直肠液中HIV-1 RNA衰减相当。
  • 与含整合酶抑制剂的三药方案一样,多替拉韦加拉米夫定可在精浆和直肠液中实现HIV-1 RNA快速抑制,尽管衰减模式与血浆不同。

研究设计与样本

  • 随机多中心先导试验,抗逆转录病毒初治男性按2:1随机分配至多替拉韦加拉米夫定组或比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺组。
  • 共入组25人,24人完成研究(多替拉韦加拉米夫定组n=16,比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺组n=8)。
  • 在基线、第3、7、14、28天及第12、24周检测血浆、精浆和直肠液中HIV-1 RNA。

主要发现

  • 两组各时间点HIV-1 RNA自基线的中位下降无显著差异。
  • 两组血浆和精浆中HIV-1 RNA达到<20拷贝/mL、直肠液中达到<20拷贝/拭子的中位时间无显著差异。
  • 多替拉韦加拉米夫定组精浆中HIV-1 RNA抑制的中位时间(7天;IQR 0-8.75)和直肠液中(10.5天;IQR 3-17.5)均短于血浆中(28天;IQR 14-84;P < .001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Decay of HIV in seminal plasma (SP) and rectal fluid (RF) has not yet been described for the antiretroviral combination of dolutegravir (DTG) + lamivudine (3TC). METHODS: In this randomized multicenter pilot trial, males who were antiretroviral naive were randomized (2:1) to DTG + 3TC or bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). HIV-1 RNA was measured in blood plasma (BP), SP, and RF at baseline; days 3, 7, 14, and 28; and weeks 12 and 24. RESULTS: Of 25 individuals enrolled, 24 completed the study (DTG + 3TC, n = 16; BIC/FTC/TAF, n = 8). No significant differences were observed between groups for median decline in HIV-1 RNA from baseline at each time point or median time to achieve HIV-1 RNA <20 copies/mL in BP and SP and <20 copies/swab in RF. HIV-1 RNA decay patterns were compared in individuals receiving DTG + 3TC. Despite significantly higher percentages for changes from baseline in BP, median (IQR) times to HIV-1 RNA suppression were shorter in SP (7 days; 0-8.75) and RF (10.5 days; 3-17.5) than in BP (28 days; 14-84; P < .001). CONCLUSIONS: Comparable HIV-1 RNA decay in BP, SP, and RF was observed between DTG + 3TC and BIC/FTC/TAF. As shown with triple-drug integrase inhibitor-based regimens, rapid HIV-1 RNA suppression in SP and RF is achieved with DTG + 3TC, despite decay patterns differing from those of BP. CLINICAL TRIALS REGISTRATION: EudraCT 2019-004109-28.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Scévola S, Niubó J, Domingo P, et al. Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. J Infect Dis. 2023. PMID: 37526315. doi:10.1093/infdis/jiad304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。